Matrix protein of vesicular stomatitis virus targets the mitochondria, reprograms glucose metabolism，and sensitizes to 2-deoxyglucose in glioblastoma

A potential therapeutic approach for Cancer treatment is target Oxidative Phosphorylation and glycolysis simultaneously. The matrix protein of vesicular stomatitis virus (VSV MP) can target the surface of mitochondria, causing morphological changes that may be associated with mitochondrial dysfunction and Oxidative Phosphorylation inhibition. Previous research has shown that mitochondrial abnormalities can direct glucose metabolism towards glycolysis. Thus, after treatment with VSV MP, glycolysis inhibition is necessary to completely block glucose metabolism and eradicate Cancer. Here, to inhibit glycolysis, the 2-deoxy-D-glucose (2-DG), a synthetic glucose analog, was used to combine with VSV MP to treat Cancer. This study aims to determine how VSV MP effects the glucose bioenergetic metabolism of Cancer cells and to evaluate the synergistic effect of 2-DG when combined with VSV. Our results indicated that in U87 and C6 glioblastoma cell lines, VSV MP caused mitochondrial membrane potential loss, cytochrome c release, and glucose bioenergetics metabolism reprogramming. When combined with 2-DG, VSV MP synergistically aggravated cell viability, Apoptosis and G2/M phase arrest. Meanwhile, the combination therapy exacerbated ATP depletion, activated AMPK, and inhibited mTOR signaling pathways. In addition, 2-DG treatment alone induced Autophagy in glioblastoma cells, however, VSV MP inhibited the Autophagy induced by 2-DG in combined treatment, and finally contributed to the enhanced cytotoxic effect of the combination strategy in U87 and C6 Cancer cells. In the orthotopic U87 glioblastoma model and subcutaneous C6 glioblastoma model, the combined treatment led to significant tumor regression and prolonged survival. A potent therapeutic approach for treating glioblastoma may be found in the combination of VSV MP and glycolytic inhibitors.